# Feng Deng

> Feng Deng is a Series A investor at Northern Light Venture Capital backing Internet. See 27 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Northern Light Venture Capital](https://shizune.co/investors/profile/northern-light-venture-capital)
- Total investments: 27
- Last investment: Jan 2023
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/feng-deng/1/976/638

Feng Deng is a Series A investor at Northern Light Venture Capital focused on Internet and Health Care. Feng co-founded Northern Light Venture Capital in 2005, a China focused fund. He has more than 15 years of technical and managerial experience in the computer, communication and data networking industries. In 1997, Feng co-founded NetScreen Technologies, and served as the Vice President of Engineering, Chief Strategy Officer and Board member.NetScreen went public on NASDAQ in 2001 and was acquired by Juniper Networks in 2004 for $4 billion. From 2004 to 2005, Feng served as VP of Corp. Strategy at Juniper Networks. Feng was awarded the Entrepreneur of the Year award in 2002 and the Innovator of the Year award in 2003. Prior to founding NetScreen, Feng worked at Intel Corp. Now he also serves on the Board of Directors of Hua Yuan Science and Technology Association (HYSTA) and is a board member of the Tsinghua University Foundation. Feng holds a MBA from the Wharton Business School, University of Pennsylvania, a MS degree in computer engineering from the University of Southern California and a MS degree in electronic engineering from Tsinghua University. He also holds five U.S. patents in computer system architecture and IC design.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Internet | 6 | 22% |
| Health Care | 5 | 19% |
| Biotechnology | 5 | 19% |
| Medical | 3 | 11% |
| Pharmaceutical | 3 | 11% |

46 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 26% |
| Series D | 5 | 19% |
| Series B | 4 | 15% |
| Series C | 4 | 15% |
| Seed | 2 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 13 | 48% |
| United States | 6 | 22% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yingke Materials | Yingke Materials is a provider of high-performance electronic paste and powder. |  | Angel | Jan 09, 2023 |  |
| Becoming | Becoming takes continuous improvement of the oral health of the Chinese people as its own responsibility. |  | Series A | Aug 02, 2022 |  |
| Xmov | Xmov is an AI company focusing on computer vision and computer graphics. | $110M | Series C | Apr 06, 2022 |  |
| Ucello Therapeutics | Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M | Series A | Feb 10, 2022 |  |
| Wancheng Gene | Wancheng Gene is a single-cell gene detection platform, which is mainly used to serve the scientific research, clinical and industrial markets with a self-developed high-throughput single-cell sequencing technology platform. The existing services of Wancheng Gene include sample preparation, database sequencing, analysis, and sample processing. Theycan be freely combined according to customer needs, and provide peripheral services such as sample preparation training and biometric analysis. | $15.7M | Series A | Dec 30, 2021 |  |
| Stellar Cyber | Stellar Cyber greatly reduces enterprise risk by the early and precise identification and remediation of all attack activities while slashing costs, retaining investments in existing tools and accelerating analyst productivity. The platform also provides effortless deployment of sensors to fill any gap on premise or in the cloud. | $38M | Series B | Nov 16, 2021 |  |
| Teon Therapeutics | Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enterPhase1b trials in 2021. | $30M | Series A | Feb 23, 2021 |  |
| Stellar Cyber | Stellar Cyber greatly reduces enterprise risk by the early and precise identification and remediation of all attack activities while slashing costs, retaining investments in existing tools and accelerating analyst productivity. The platform also provides effortless deployment of sensors to fill any gap on premise or in the cloud. | $7.1M | Series A | Oct 01, 2019 |  |
| Stellar Cyber | Stellar Cyber greatly reduces enterprise risk by the early and precise identification and remediation of all attack activities while slashing costs, retaining investments in existing tools and accelerating analyst productivity. The platform also provides effortless deployment of sensors to fill any gap on premise or in the cloud. | $13.2M | Series A | Feb 26, 2019 |  |
| Cytek Biosciences | Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and cliniciansall over the world.Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. |  | Series C | Sep 24, 2018 |  |

10 of 27 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 4 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 4 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 4 deals together
- [Valley Capital Partners](https://shizune.co/investors/profile/valley-capital-partners) — VC Fund, 4 deals together
- [DCM Ventures](https://shizune.co/investors/profile/dcm) — VC Fund, 2 deals together

## About Northern Light Venture Capital

VC Fund · Beijing, China

Northern Light Venture Capital was founded by general partners Feng Deng and Yan Ke on January 1, 2005. Currently it is managed by five Managing Directors. It manages approximately US$ 1.5 billion in committed capital with 4 US$ funds and 4 RMB funds, investing in more than 180 portfolio companies and seed investments to date.NLVC is led by apartnership of accomplished local Chinese and ""returnee"" executives (""returnees"" are those who grew up in mainland China but studied or worked abroad before returning) with significant investing and entrepreneurial accomplishments. Its management team includes Feng Deng, former member of the board at NetScreen (a pioneering IT security firm), Yan Ke, vice President of Netscreen, and Lei Yang, chairman of Vantage Point Venture Partners.NLVC is a China concept venture capital firm focused on early and growth stage opportunities which targets businesses that leverage China’s industrial, economic, or human resources to build exceptional, lasting enterprises in the global economy.NLVC focuses on early and growth stage opportunities in information technology, new media, TMT, clean technologies, consumer service and healthcare. Portfolio companies include Meituan.com, Kaixin001.com, Gogo.com, redbaby.com, MasaMaso.com, and Velo City.

5 contacts available at Northern Light Venture Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Figo Zhang | Partner | https://shizune.co/investors/profile/figo-zhang |
| Feng Deng | Founding General Partner | https://shizune.co/investors/profile/feng-deng |
| Lixin Li | Managing Director | https://shizune.co/investors/profile/lixin-li |
| Lu Lin | Executive Director | https://shizune.co/investors/profile/lu-lin |
| Pandy Song | Associate | https://shizune.co/investors/profile/pandy-song |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Feng Deng invest in?

Feng Deng invests primarily in Internet, Health Care and Biotechnology startups, most often at Series A and Series D stage. Most of the 27 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Feng Deng last invest?

The most recent investment recorded for Feng Deng closed in Jan 2023. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co